NCT00020189已完成2 期
A Phase II Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have recurrent or metastatic head and neck cancer.
详细描述
OBJECTIVES:
- Determine the standard response rate (complete response and partial response) and duration of response in patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with flavopiridol.
- Determine the qualitative and quantitative toxic effects of this regimen in these patients.
- Determine the progression-free and overall survival of patients treated with this regimen.
- Determine the effects of anti-platelet agents, aspirin and clopidogrel bisulfate, on the pharmacology of flavopiridol in these patients.
- Determine the effects of prophylactic anticoagulation with anti-platelet agents, aspirin and clopidogrel bisulfate, on the incidence of flavopiridol-related thrombosis in these patients.
OUTLINE: Patients receive flavopiridol IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Patients also receive oral aspirin and clopidogrel bisulfate beginning on day 0 and continuing throughout the study.
Patients are followed until death.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically proven squamous cell carcinoma of the head and neck
- •Metastatic disease at diagnosis OR
- •Persistent, metastatic, or recurrent disease after prior definitive surgery and/or radiotherapy
- •No undifferentiated and nonkeratinizing carcinomas, including lymphoepitheliomas of all locations
- •No nasopharynx tumors
- •Bidimensionally measurable disease
- •Patients whose only measurable disease is within a prior radiotherapy port must have clearly progressive disease
- •No metastatic or leptomeningeal CNS disease
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status:
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Platelet count greater than 100,000/mm^3
- •Absolute granulocyte count greater than 1,500/mm^3
- •See Other (Prior/Concurrent Therapy)
- •SGOT and SGPT less than 2.5 times normal
- •Bilirubin less than 1.5 times normal
- •No history of hypercoagulopathies (e.g., protein C deficiency, protein S deficiency, or lupus anticoagulant)
- •Creatinine no greater than 1.5 mg/dL OR
- •Creatinine clearance at least 60 mL/min
- •Calcium no greater than normal
- •No hypercalcemia refractory to bisphosphonates
- •Cardiovascular:
- •No unstable or newly diagnosed angina pectoris
- •No myocardial infarction within the past 6 months
- •No class II-IV congestive heart failure
- •No history of symptomatic carotid disease
- •No concurrent asymptomatic carotid artery occlusion (70% or greater) in one or both arteries by Doppler ultrasound
- •No symptomatic atherosclerosis
- •No thrombotic events within the past 6 months
- •No aspirin-induced asthma
- •No inability to take aspirin or clopidogrel bisulfate due to contraindications, allergies, or pre-existing medical conditions (e.g., active peptic ulcer disease or history of undiagnosed non-occult, non-hemorrhoidal gastrointestinal or other bleeding sources within the past 6 months)
- •No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer that is currently in complete remission
- •HIV negative
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 3 months after study
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •No concurrent biologic therapy
- •Chemotherapy:
- •At least 4 weeks since prior chemotherapy and recovered
- •No prior flavopiridol
- •No more than 3 prior systemic chemotherapy regimens for recurrent or metastatic disease
- •No other concurrent chemotherapy
- •Endocrine therapy:
- •No concurrent hormonal therapy except oral contraceptives
- 另有 11 项未显示
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Flavopiridol in Treating Patients With Refractory CancerUnspecified Adult Solid Tumor, Protocol SpecificSmall Intestine CancerProstate CancerLymphomaNCT00019344National Cancer Institute (NCI)
已完成
2 期
Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney CancerKidney CancerNCT00016939SWOG Cancer Research Network
已完成
2 期
Flavopiridol in Treating Patients With Metastatic Malignant MelanomaMelanoma (Skin)NCT00005971NCIC Clinical Trials Group17
已完成
2 期
Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue SarcomaSarcomaNCT00005974NCIC Clinical Trials Group18
已完成
2 期
Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial CancerEndometrial CancerNCT00023894Gynecologic Oncology Group